JUST IN: OKYO Pharma Limited (NASDAQ: OKYO) – 70% Surge Amidst Positive Data in Long-Term Stability of Urcosimod
Published: Mon, 03/31/25
Updated: Mon, 03/31/25
Get the Full Story - Breaking News Released! Download our Mobile App📱
SPONSORED
.
JUST IN: OKYO Pharma Limited (NASDAQ: OKYO) – 70% Surge Amidst Positive Data in Long-Term Stability of Urcosimod
OKYO Pharma Limited
(NASDAQ: $OKYO)
===========================
Alert Price - $1.26 per share
Market Cap - $42.794M
Avg. Volume - $194,306
Members,
We're excited to present our latest pick, OKYO Pharma Limited (NASDAQ: OKYO)—a clinical-stage biopharmaceutical company driving innovation in the field of ocular therapeutics. With a focus on developing novel treatments for dry eye disease and other inflammatory eye conditions, NASDAQ: OKYO is positioning itself as a potential leader in a high-demand market.
OKYO could be on the cusp of a significant breakout. We believe NASDAQ: OKYO could be a boomer trade with a potential 70% surge in sight, offering a compelling short-term opportunity while also holding long-term promise as a transformative player in the biotech and ophthalmology space.
Technical Overview
OKYO Pharma Limited (NASDAQ: OKYO) shares are
down 7.33% in Monday's market trading. The stock’s Relative Strength Index (RSI) stands at 47, which, despite the recent decline, suggests that bullish momentum is building. The RSI is neither overbought nor oversold, indicating a healthy consolidation phase before a potential upward move.
For OKYO Pharma Limited (NASDAQ: OKYO) shares, the immediate support lies in the $0.926 pivot level not so far from the current price will serve as a springboard towards greater highs with eyes set on 70% gain as confirmed by the chart pattern.
Similarly, a breakout above the $1.55 resistant level could pave the way for the anticipated 70% surge on the horizon without testing the support point aforementioned above.
The NASDAQ: OKYO chart pattern is displaying a well-defined structure, with clear support and resistance points established. As shown in the chart, the stock has been
consolidating between a strong support level around $0.9000 and a resistance zone near $1.6000. This range-bound movement, combined with recent price action testing the support and showing signs of a bounce, suggests that OKYO may be gearing up for a breakout above the resistance.
The stock is currently trading at $1.363,
up $0.103 (8.16%) in after-hours trading, reflecting strong momentum for a potential 70% surge. Additionally, the MACD indicator chart shows a bullish crossover, with the MACD line moving above the signal line, further supporting the likelihood of an upward move toward the $2.30 range if the breakout is confirmed.
Given these
technical alignments, NASDAQ: OKYO could be setting up for an 70% surge, offering traders a strategic opportunity to capitalize on its momentum before the breakout fully unfolds.
About OKYO Pharma Limited (NASDAQ: OKYO)
OKYO Pharma Limited (NASDAQ: OKYO)is a United Kingdom-based clinical-stage biopharmaceutical company, founded in 2007, that focuses on developing innovative therapeutics for inflammatory eye diseases and ocular pain. The company went public on May 17, 2022, and operates within the healthcare sector, specializing in ocular health advancements. OKYO is led by CEO Gary S. Jacob and a dedicated team, working to address
unmet needs in ophthalmology.
Its lead product candidate, OK-101, is currently in Phase II clinical trials for the treatment of dry eye disease, in
Phase I clinical trials for neuropathic corneal pain, and in preclinical trials for allergic conjunctivitis and uveitis. Additionally, the company is developing OK-201, which is in preclinical trials targeting dry eye disease and neuropathic chronic pain.
Headquartered in London, OKYO Pharma Limited continues to advance its pipeline, positioning itself as a potential leader in the ocular therapeutics space.
Gary S. Jacob, Ph.D., Chief Executive Officer of Okyo Pharma commented:
“Success for a drug in clinical development is not just about clinical data obtained from clinical trials but also requires a considerable amount of successful effort with what are called the chemistry, manufacturing and controls (CMC) part of a successful submission package to the FDA, One of the major requirements for drug approval is that the drug is stable to degradation for a considerable period of time. This addresses the issue of shelf stability for a drug, and
the fact that we have now established this for urcosimod is a critical positive step in meeting CMC requirements for a successful New Drug Application (NDA) with FDA.”
OKYO Pharma Limited (NASDAQ: OKYO) announced today:
"That it has been notified that the Chief Executive Officer, Gary S. Jacob, has purchased 10,000 of the Company’s ordinary shares on NASDAQ at a price of US$1.04 per share."
"In our view, OKYO is uniquely positioned to
emerge as a key player in the ocular treatment arena. OKYO Pharma is focused on developing OK-101 to treat NCP which presently has no FDA approved drug to treat this debilitating ocular disease. OKYO Pharma commenced its Phase 2 trial of OK-101 in October 2024 and results are expected by year-end 2025."
Goldman further opined:
"OKYO is the first company to be granted an investigational new drug (IND) application for NCP by the FDA for clinical trials in NCP patients, and the first company to launch a clinical trial in NCP patients specifically diagnosed with NCP. This trial is on the heels of a favorable DED Phase 2 trial of OK-101 which notably demonstrated
statistical significance in an ocular pain secondary endpoint,"
“We are excited to announce the enrollment of the first patient in our Phase 2 clinical trial of OK-101,”
He further stated:
“This is a key step forward in our mission to provide relief for patients suffering from neuropathic corneal pain, a chronic condition for which no FDA-approved treatments
exist today. OK-101 represents a potential breakthrough in the treatment of this condition, and we remain committed to advancing its development with the goal of delivering a novel therapeutic option to patients in need.”
Why OKYO Pharma Limited (NASDAQ: OKYO) Stands Out
OKYO Pharma Limited (NASDAQ: OKYO) is revolutionizing ocular
therapeutics with innovative treatments aimed at inflammatory eye diseases and ocular pain. Unlike conventional biopharmaceutical companies, OKYO is taking a next-generation approach to drug development, focusing on targeted therapies that address the underlying causes of conditions like dry eye disease and neuropathic corneal pain, rather than merely managing symptoms.
OKYO Pharma Ltd. (NASDAQ: OKYO), is a biopharmaceutical company dedicated to developing an innovative treatment for neuropathic corneal pain and dry eye disease. Through its proprietary chemerin peptide, OK-101, the company aims to provide targeted therapy that not only alleviates pain but also controls inflammation, while enhancing ocular residence time for more effective, lasting relief.
This unique approach positions OKYO as a potential game-changer in the ocular health space, offering solutions that could significantly improve patient outcomes in areas with substantial unmet medical needs.
Under the leadership of CEO Gary S. Jacob, OKYO Pharma has positioned itself as a high-growth biotech disruptor with the potential to redefine how ocular diseases are treated. With a robust research pipeline, strategic innovation in ocular therapeutics, and a commitment to delivering life-changing treatments, OKYO is not just another biotech stock—it’s a pioneer in the next era of ophthalmology breakthroughs. This unique approach positions OKYO as a potential game-changer in
the ocular health space, offering solutions that could significantly improve patient outcomes in areas with substantial unmet medical needs.
The Rising Demand for Innovative Treatments in Ocular Pain and Inflammatory Eye Diseases
The
prevalence of ocular pain and inflammatory eye diseases is increasing globally, leading to a heightened demand for advanced therapeutic solutions. Conditions such as uveitis, conjunctivitis, and dry eye disease are becoming more common, particularly among the aging population. This trend underscores the necessity for innovative treatments to address the growing patient needs.
Market Growth and Investment in Ocular Inflammation Treatment
The global ocular inflammation treatment market, valued at approximately USD 7.5 billion in 2023, is projected to grow at a compound
annual growth rate (CAGR) of around 4.5% from 2024 to 2032. This growth is driven by the rising incidence of ocular inflammatory conditions and increased investment in research and development for novel therapies.
The Expanding Chronic Ocular Pain Market Similarly, the chronic ocular pain market is experiencing significant expansion. Valued at USD 7.19 billion in 2023, it is anticipated to reach USD 12.44 billion by 2032,
reflecting a CAGR of 6.58%. Factors contributing to this growth include the aging global population and the increasing prevalence of conditions like dry eye disease and autoimmune disorders.
Advancements in Drug Formulations and Treatments In response to these trends, pharmaceutical companies are intensifying their research efforts to develop targeted therapies. Advancements in drug formulations and delivery methods are enhancing treatment efficacy and patient outcomes. For instance, the introduction of biologics and biosimilars has revolutionized the management of various eye diseases, offering more effective and personalized treatment
options.
OKYO Pharma Limited
(NASDAQ: OKYO) - Key Metrics
Total Valuation - Market Cap: $42.794 - Enterprise Value: $43.47M
OKYO Pharma Limited (NASDAQ: OKYO) has a market cap or net worth of $42.794 million as of March 31,
2025.
Important Dates - The next estimated earnings date is
Tuesday, April 8, 2025, before market open.
Share Statistics - Current Share Class 33.94M - Shares Outstanding 33.94M - Shares Change (YoY) +42.96% - Shares Change (QoQ) +30.56% - Owned by Insiders
(%) 29.27%
HC Wainwright & Co. analyst Yi Chen has a "Strong Buy" rating on OKYO stock with a $7 price target, projecting a +455.56% price increase.
Why Now is the
Time to Consider OKYO Pharma Limited (NASDAQ: OKYO)
OKYO Pharma (NASDAQ: OKYO) offers a compelling case for investors at its current levels, supported by robust technical indicators and its pioneering work in ocular disease treatments. The OKYO chart pattern is displaying a well-defined structure, with clear support and resistance points established. As shown in the chart, the stock has been consolidating between a strong support level around $0.9000 and a resistance zone near $1.6000. This
range-bound movement, combined with recent price action testing the support and showing signs of a bounce, hints at a 70% breakout.
With the RSI at 47, OKYO is neither overbought nor oversold, signaling ample room for an upside breakout. Additionally, it's trading above its moving averages, a setup that often allows for
high-percentage gains when momentum kicks in—setting the stage for a potential 70% surge.
Beyond the charts, OKYO Pharma is making waves in the biotech space with its lead candidate, OK-101, a novel therapy targeting inflammatory eye diseases like dry eye disease and neuropathic corneal pain—conditions with massive unmet needs
in a multi-billion-dollar market.
As a clinical-stage company, OKYO’s innovative approach positions it as a leader in ocular therapeutics, with the potential for significant value creation as its trials progress.
Institutional interest
is also on the rise, reflecting growing confidence in OKYO’s long-term prospects. With a breakthrough therapy in a high-demand sector, OKYO combines the allure of an opportunistic trade with a solid growth narrative—a rare find in biotech that could yield exponential returns.
Don’t sleep on this—OKYO Pharma (NASDAQ: OKYO) could be on the cusp of a major revaluation and now may be the perfect moment to get in ahead of the crowd!
As always, we urge you to do your own due diligence and evaluate how OKYO Pharma (NASDAQ: OKYO) aligns with your investment goals.
This newsletter is a Paid Advertisement, not a recommendation nor an offer to buy or sell securities. This newsletter is owned, operated and edited by DEXWireNews LLC. Any wording found in this e-mail or disclaimer referencing to “I” or “we” or “our” refers to DEXWireNews LLC.
You are reading this
newsletter because you have subscribed via our opt-In signup form on our website. If you have been subscribed by accident, then you may unsubscribe by clicking the link below.
By reading our newsletter and our website you agree to the terms of our disclaimer, which are subject to change at any time. We are not registered or
licensed in any jurisdiction whatsoever to provide investing advice or anything of an advisory or consultancy nature, and are therefore are unqualified to give investment recommendations. Always do your own research and consult with a licensed investment professional before investing. This communication is never to be used as the basis of making investment decisions, and is for entertainment purposes only. At most, this communication should serve only as a starting point to do your own research
and consult with a licensed professional regarding the companies profiled and discussed. Conduct your own research. Companies with low price per share are speculative and carry a high degree of risk, so only invest what you can afford to lose. By using our service you agree not to hold our site, its editor’s, owners, or staff liable for any damages, financial or otherwise, that may occur due to any action you may take based on the information contained within our newsletters or on our
website.
We do not advise any reader take any specific action. Losses can be larger than expected if the company experiences any problems with liquidity or wide spreads. Our website and newsletter are for entertainment purposes only. Never invest purely based on our alerts. Gains mentioned in our newsletter and on our website may be
based on end-of-day or intraday data. This publication and their owners and affiliates may hold positions in the securities mentioned in our alerts, which we may sell at any time without notice to our subscribers, which may have a negative impact on share prices. If we own any shares we will list the information relevant to the stock and number of shares here: We do NOT own shares of any of the companies mentioned herewithin, nor intend to buy any in the future.
You should read and review, if and to the extent available, any information concerning an advertised company available at the web sites of the U.S. Securities and Exchange Commission (the "SEC") at http://www.sec.gov and the Financial Industry Regulatory Authority (the "FINRA") at http://www.FINRA.org. We also strongly recommend that you read the SEC advisory to investors concerning Internet Stock Fraud
at https://www.sec.gov/reportspubs/investor-publications/investorpubscyberfraudhtm.html, as well as related information published on how to invest carefully. You are responsible for verifying all claims and conducting your own
due diligence. You agree and acknowledge that any hyperlinks to the website of (1) an advertised company, (2) the party issuing or preparing the information for the advertised company, or (3) other information contained in our disseminated emails is provided only for your reference and convenience. We are not responsible for the accuracy or reliability of these external sites, nor are we responsible for the content, advertising, opinions, products or other materials on external sites or
information sources. If you use, act upon or make decisions in reliance on information contained in any disseminated email or any hyperlink, you do so at your own risk and agree to hold us, our officers, directors, shareholders, affiliates and agents harmless. You acknowledge that you are not relying on us, and we are not liable for, any actions taken by you based on any information contained in any disseminated email or hyperlink. You also acknowledge that we are not an investment advisory
service, a broker-dealer or an investment adviser. You acknowledge that you will consult with your own advisers regarding any decisions as to any advertised company.
Our business model is to receive financial compensation to promote public companies. We have been compensated ten thousand dollars electronically via bank wire by One
Eyed Jack Enterprises LLC for an advertising / marketing campaign for OKYO Pharma Limited (NASDAQ: OKYO) beginning on 3/31/2025 and ending on 4/2/2025. DEXWireNews may receive additional campaigns in the future by One Eyed Jack Enterprises LLC to distribute media for OKYO Pharma Limited (NASDAQ: OKYO).
Any compensation is a major
conflict of interest in our ability to be unbiased. Therefore, this communication should be viewed as a commercial advertisement only. We have not investigated the background of the hiring third party or parties. The third party, profiled company, or their affiliates likely wish to liquidate shares of the profiled company at or near the time you receive this communication, which has the potential to hurt share prices. Any non-compensated alerts are purely for the purpose of
expanding our database for the benefit of our future financially compensated investor relations efforts. Frequently companies profiled in our alerts may experience a large increase in volume and share price during the course of investor relations marketing, which may end as soon as the investor relations marketing ceases. The investor relations marketing may be as brief as one day, after which a large decrease in volume and share price is likely to occur. Our emails may contain forward looking
statements, which are not guaranteed to materialize due to a variety of factors.
We do not guarantee the timeliness, accuracy, or completeness of the information on our site or in our newsletters. The information in our email newsletters and on our website is believed to be accurate and correct, but has not been independently
verified and is not guaranteed to be correct. The information is collected from public sources, such as the profiled company’s website and press releases, but is not researched or verified in any way whatsoever to ensure the publicly available information is correct. Furthermore, we often employs independent contractor writers who may make errors when researching information and preparing these communications regarding profiled companies. Independent writers’ works are double-checked and
verified before publication, but it is certainly possible for errors or omissions to take place during editing of independent contractor writer’s communications regarding the profiled company(s). You should assume all information in all of our communications is incorrect until you personally verify the information, and again are encouraged to never invest based on the information contained in our written communications. The information in our disclaimers is subject to change at any time without
notice.
Will everyone receive the Information at the same time? No. The Information may be sent to potential investors at different times that
are minutes, hours, days or even weeks apart.
How is a potential investor impacted if they receive the Information later than other investors? If the trading volume and price of a Profile Issuer’s securities increases after the Information is provided to an earlier group of investors, then subsequent investors will pay inflated prices for any securities of the Profiled Issuers that they purchase. This will likely result in the Profiled Issuers having trading losses.
